Program
admilparant
Also written as “BMS-986278”, “Admilparant” and “BMS-986278 Batched method, Dose B”.
Its studies are mostly in Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis · Kidney Failure, Chronic · Liver Diseases, led by Bristol-Myers Squibb.
Drug pageAdmilparant: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 183 open or running | phase 3since Aug 15, 2023 | Feb 5, 2018 | Dec 27, 2027phase 3 · NCT06025578 |
- Named in Bristol-Myers Squibb’s own pipeline as
admilparant
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Feb 5, 2018.
- May 21, 2019Phase 1 study in Idiopathic Pulmonary FibrosisNCT03981094 · 22 enrolled · United States
- Mar 12, 2020Phase 2 study in Pulmonary FibrosisNCT04308681 · 403 enrolled · United States, Argentina, Australia and more
- Jul 9, 2020Phase 1 study in Healthy ParticipantsNCT04468815 · 24 enrolled · United States
- Sep 24, 2020Phase 1 study in Healthy VolunteersNCT04567667 · 9 enrolled · United States
- Dec 20, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT05684289 · 61 enrolled · United States
- Mar 28, 2023Phase 1 study in Healthy VolunteersNCT05805904 · 24 enrolled · China
- Aug 15, 20232 phase 3 studiesNCT06003426, NCT06025578
- Feb 29, 2024Named admilparantINNProposed as its International Nonproprietary Name in WHO's List 130 · before, BMS-986278, BMS 986278
- May 17, 2024Phase 1 study in Liver DiseasesNCT06425198 · 37 enrolled · United States
- Aug 21, 2024Phase 1 study in Healthy ParticipantsNCT06568458 · 71 enrolled · United States
- Nov 28, 2024Phase 1 study in Healthy VolunteersNCT06715683 · 48 enrolled · United States
- Dec 4, 20242 phase 1 studiesNCT06723535, NCT06746402
- Nov 4, 2025Phase 1 study in Healthy ParticipantsNCT07225647 · 56 enrolled · United States
- Feb 12, 2026Phase 1 study in Healthy VolunteersNCT07422298 · 32 enrolled · United States
- Feb 25, 2026Phase 3 study in Pulmonary FibrosisNCT07441408 · 2,380 planned · United States, Argentina, Australia and more
Ahead
- Dec 27, 2027Primary completion: phase 3 study in Pulmonary FibrosisNCT06025578
- Nov 22, 2029Primary completion: phase 3 study in Pulmonary FibrosisNCT07441408
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07441408Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Not yet recruiting | Nov 22, 2029 | 2,380 |
| NCT07422298Healthy Volunteers · United States | 1 | Completed | Jun 14, 2026 | 32 |
| NCT07225647Healthy Participants · United States | 1 | Completed | Jan 5, 2026 | 56 |
| NCT06746402Healthy Volunteers · United States | 1 | Completed | Sep 11, 2025 | 42 |
| NCT06723535Kidney Failure, Chronic · United States | 1 | Completed | Sep 16, 2025 | 27 |
| NCT06715683Healthy Volunteers · United States | 1 | Completed | Mar 16, 2025 | 48 |
| NCT06568458Healthy Participants · United States | 1 | Completed | Feb 27, 2025 | 71 |
| NCT06425198Liver Diseases · United States | 1 | Completed | Dec 30, 2024 | 37 |
| NCT06025578Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 27, 2027 | 1,057 |
| NCT06003426Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 6, 2026 | 1,255 |
| NCT05805904Healthy Volunteers · China | 1 | Completed | May 23, 2023 | 24 |
| NCT05684289Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | May 2, 2023 | 61 |
| NCT04567667Healthy Volunteers · United States | 1 | Completed | Apr 11, 2021 | 9 |
| NCT04468815Healthy Participants · United States | 1 | Completed | Oct 7, 2020 | 24 |
| NCT04308681Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Completed | Aug 4, 2022 | 403 |
| NCT03981094Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | Jul 27, 2019 | 22 |
| NCT03712540Healthy Participants · United States | 1 | Completed | Nov 8, 2018 | 39 |
| NCT03429933Healthy Participants · Netherlands, United Kingdom | 1 | Completed | Mar 2, 2019 | 112 |
How it is read
Names in the registry
- “BMS-986278”, 13 entries
- “Admilparant”, 1 entry
- “BMS-986278 Batched method, Dose B”, 1 entry
- “BMS-986278 Continuous method”, 1 entry
- “BMS 986278”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Fibrosis, 3 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Kidney Failure, Chronic, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.